The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| Acceleron Pharma Inc. | COM | 00434H108 | 2,491 | 94,403 | SH | SOLE | 94,403 | 0 | 0 | ||
| Aerie Pharmaceuticals, Inc. | COM | 00771V108 | 11,639 | 957,126 | SH | SOLE | 957,126 | 0 | 0 | ||
| Aimmune Therapeutics, Inc. | COM | 00900T107 | 4,814 | 355,020 | SH | SOLE | 355,020 | 0 | 0 | ||
| Akari Therapeutics, PLC | SPONSORED ADR | 00972G108 | 3,695 | 263,921 | SH | SOLE | 263,921 | 0 | 0 | ||
| Alder BioPharmaceuticals, Inc. | COM | 014339105 | 31,312 | 1,278,570 | SH | SOLE | 1,278,570 | 0 | 0 | ||
| Ardelyx, Inc. | COM | 039697107 | 5,038 | 648,340 | SH | SOLE | 648,340 | 0 | 0 | ||
| Avexis, Inc. | COM | 05366U100 | 4,582 | 168,195 | SH | SOLE | 168,195 | 0 | 0 | ||
| Bellicum Pharmaceuticals, Inc. | COM | 079481107 | 1,926 | 205,990 | SH | SOLE | 205,990 | 0 | 0 | ||
| BioDelivery Sciences International, Inc. | COM | 09060J106 | 670 | 207,498 | SH | SOLE | 207,498 | 0 | 0 | ||
| Dimension Therapeutics, Inc. | COM | 25433V105 | 770 | 98,297 | SH | SOLE | 98,297 | 0 | 0 | ||
| Editas Medicine, Inc. | COM | 28106W103 | 501 | 14,500 | SH | SOLE | 14,500 | 0 | 0 | ||
| Epizyme, Inc. | COM | 29428V104 | 5,779 | 476,777 | SH | SOLE | 476,777 | 0 | 0 | ||
| Global Blood Therapeutics, Inc. | COM | 37890U108 | 7,882 | 497,000 | SH | SOLE | 497,000 | 0 | 0 | ||
| ImmunoGen, Inc. | COM | 45253H101 | 365 | 42,815 | SH | SOLE | 42,815 | 0 | 0 | ||
| Intersect ENT, Inc. | COM | 46071F103 | 3,202 | 168,550 | SH | SOLE | 168,550 | 0 | 0 | ||
| Lipocine Inc. | COM | 53630X104 | 4,031 | 397,107 | SH | SOLE | 397,107 | 0 | 0 | ||
| NeuroDerm Ltd. | ORD SHS | M74231107 | 4,128 | 292,371 | SH | SOLE | 292,371 | 0 | 0 | ||
| Orexigen Therapeutics, Inc. | COM | 686164104 | 1,703 | 3,027,354 | SH | SOLE | 3,027,354 | 0 | 0 | ||
| Regenxbio Inc. | COM | 75901B107 | 1,080 | 100,000 | SH | SOLE | 100,000 | 0 | 0 | ||
| Regulus Therapeutics Inc. | COM | 75915K101 | 5,468 | 789,091 | SH | SOLE | 789,091 | 0 | 0 | ||
| Sangamo Biosciences, Inc. | COM | 800677106 | 3,296 | 544,816 | SH | SOLE | 544,816 | 0 | 0 | ||
| WAVE Life Sciences Ltd. | SHS | Y95308105 | 17,855 | 1,411,749 | SH | SOLE | 1,411,749 | 0 | 0 | ||
| Zafgen, Inc. | COM | 98885E103 | 7,020 | 1,050,837 | SH | SOLE | 1,050,837 | 0 | 0 | ||